Alios BioPharma Inc.

Alios BioPharma aims to create an improved version of interferon--the only drug that could be considered a broad-spectrum antiviral--to help patients who do not respond well to currently marketed forms of the protein. Alios also plans to develop a small-molecule drug that can be given orally yet carry out a key function of the interferon response-degrading viral genomes. Such a drug could potentially treat influenza, hepatitis C and B, HIV, and a host of other viruses.